MLD to present at World Orphan Drug Congress Europe

MLD is happy to announce that not only are we attending this year’s World Orphan Drug Congress (WODC) Europe in Barcelona, we have been offered two presenting spots at the conference. WODC Europe is the leading conference in Europe on the development of drugs for orphan diseases. The small patient populations in these orphan diseases means that the traditional drug development guidelines become impossible to follow. MLD is looking forward to talking with other orphan drug developers to learn what approaches they have taken and about the regulatory pathway for rare disease drugs in Europe.

Shawn Ritchie, CEO and Chief Scientific Officer, will be providing a talk on October 23rd entitled “Metabolic plasmalogen replacement therapy for a rare peroxisomal disorder” which will provide a corporate update on our PPI-1011 program. Later that day, Tara Smith, Executive VP, is giving a talk entitled “Lessons learned from the planning and execution of a 5-year prospective natural history study in an ultra-orphan paediatric disorder.”

Anyone who is attending the conference and is interested in discussing the program more is encouraged to reach out through the conference’s partnering app.